Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-alpha. Infliximab prevents the interaction of TNF-alpha with TNF-alpha receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research[1][2]. The component ratio of this product is Active ingredient : Excipients = 9 : 47.
Molecular Weight:
(145.98 kDa)
Purity:
90.30
CAS Number:
[170277-31-3]
Target:
TNF Receptor
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted